Jotbody專注于發現新型sdAb。高質量、特異性和親和力使其sdAb成為研究、診斷和治療應用的合適選擇！

Conventional antibody (e.g., monoclonal IgGs) has limitations: high production costs, poor tissue penetration, long serum half-life due to their large sizes (150 kDa) and complex structures, which hinder the widespread use as therapeutics and imaging reagents.

傳統抗體(例如單克隆IgG)存在生產成本高、組織滲透性差、體積大(150 kDa)和結構複雜導致的血清半衰期長等局限性，阻礙了其作為治療和成像試劑的廣泛應用。

Single Domain Antibody (sdAb) is the smallest known antigen-binding fragment. The size of sdAb is one-tenth of conventional antibody. In this respect, sdAb holds a plethora of intrinsic advantages: high affinity, recognition of hidden antigenic sites, improved tissue penetration, ability to trespassing the blood brain barrier, better thermal and chemical stability, high solubility, high modularity, large-scale production, and readily re-formatted to be used across many scientific disciplines.

納米抗體(Single Domain Antibody, sdAb)是已知最小的抗原結合片段，其大小是常規抗體的十分之一。此外，納米抗體擁有很多的內在優勢：高親和力，對隱藏抗原位點的識別，高組織穿透能力，突破血腦屏障的能力，更好的熱和化學穩定性，高溶解性，高模組化，易大規模生產，易於改造以應用於不同用途。

Jotbody adopts a cost-effective and short-cycle workflow for the discovery of sdAb from Camel, Alpaca, Llama (VHH) and Shark (VNAR). Through comprehensive technology platforms and service portfolios, our team is best at discovering unique sdAb candidates to satisfy your specific requirements.

艾美捷Jotbody 采用低成本、短週期的開發流程用於發現源自駱駝、羊駝和鯊魚的納米抗體。通過全面的技術平臺和服務組合，并擅長發現獨丨特的納米抗體候選分子，以滿足一站式需求。

Jotbody在生物化學、免疫學和藥物傳遞領域具有強大的研究背景，主要研發采用低成本、短周期的開發流程，生產源自駱駝、羊駝和鯊魚的納米抗體候選分子，具有非常大的潛力。艾美捷科技是Jotbody的中國代理商，為科研工作者提供優質的產品與服務。